Figure 7 (IMAGE)
Caption
Anti-STn ADCs impede OvCa xenograft growth in vivo and target STn+ cells. (A) Mice bearing tumors derived from OVCAR3 were treated with vehicle, unconjugated S3F, S3F-CL-MMAE, unconjugated 2G12-2B2, or 2G12-2B2-CL-MMAE. Tumors were measured twice weekly, and the percentage change in tumor volume compared to the baseline volume (100%) is shown. Error bars represent the mean ± SEM *p < 0.05. (B) Xenografts collected at the end of the in vivo treatment were examined to assess the relative frequency of STn-/CD133-, STn+/CD133-, STn-/CD133+ and STn+/CD133+ sub-populations.
Credit
Corporate Contact: Siamab Therapeutics Jenna Stein, 857-222-5817 jenna@siamab.com
Usage Restrictions
None
License
Licensed content